Table 2: Therapeutic applications of bone marrow-derived HSCs in liver cirrhosis patients.
| Cell type | Dose | Route | Sample size (n) | Outcome | Reference |
| BM-HSC | Single median dose/5 × 109 | Peripheral vein | 10 | Increased serum albumin; Decreased CPS | [20] |
| BM-HSC | Single median dose/2 × 108 | Portal vein (n = 3); Hepatic artery (n = 2) | 5 | Increased serum albumin; Decreased bilirubin and ascites | [50] |
| BM-HSC | Single median dose/2.3 × 108 | Hepatic artery | 9 | Increased ALT, AST; Decreased CPS, serum bilirubin and ascites | [51] |
| BM-HSC | Single median dose/range between 1 × 106 - 2 × 108 | Portal vein/hepatic artery | 5 | Increased serum albumin; Decreased serum bilirubin | [52] |